Galantime for dementia in people with Down syndrome

Mohan M, Bennett C, Carpenter PK

Published Online:

January 21, 2009

The drug galantamine has been reported to have benefits for people with mild to moderate Alzheimer's disease who do not have Down syndrome. However, people with DS tend to present with AD at a much younger age than the general population as well as being physically different in terms of size, metabolism and heart rate, and may therefore have different requirements. This review identified no randomised controlled trials of galantamine in people with Down syndrome. Further research is needed.

Abstract (click to read)

Background:

Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Galantamine both inhibits the activity of acetylcholinesterase and increases the level of acetylcholine. Galantamine can improve cognitive function and slow the decline of AD in the general population over time. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.

Objectives:

To determine the effectiveness and safety of galantamine for people with DS who develop AD.

Search strategy:

CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of galantamine as well as experts in the field, to ask about reports of unpublished or ongoing trials.

Selection criteria:

Randomised controlled trials of participants with DS and AD in which treatment with galantamine was administered compared with a placebo group.

Data collection and analysis:

No study was identified which met inclusion criteria for this review.

Main results:

No study was identified which met inclusion criteria for this review.

Authors' conclusions:

As there are no included trials, recommendations cannot be made about galantamine for AD in DS. Well-designed, adequately powered studies are required.

This record should be cited as:

Mohan M, Bennett C, Carpenter PK. Galantamine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007656. DOI: 10.1002/14651858.CD007656

Assessed as up to date:

October 30, 2008

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Developmental, Psychosocial and Learning Problems Group

Health topics:

Developmental, psychosocial, and learning problems > Developmental problems > Neurodevelopmental disorders

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Galantime for dementia in people with Down syndrome

More like this

Copyright © 2012 - The Cochrane Collaboration